Highlights Laboratorio Farmaceutico Erfo S.p.A.

Stocks

ERFO

IT0005497885

Pharmaceuticals

Market Closed - Borsa Italiana 16:45:00 30/09/2026 BST			5-day change	1st Jan Change
1.110 ^EUR	-0.89%		+2.30%	-24.49%

09-27	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-31	Milan in the pink at the open, oil stocks lead the MIB	AN

Highlights

09-27	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-27	Laboratorio Farmaceutico Erfo closes half-year with revenue up 2%	AN
07-06	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
06-22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
06-19	Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired.	CI
06-15	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
05-21	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
05-21	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
04-12	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025	AN
02-19	Erfo Increases EBITDA in 2025; Revenues More Than Double	AN
02-19	Laboratorio Farmaceutico Erfo FY EBITDA EUR 2.0 Mln	RE
11-21	Erfo Pharmaceutical Laboratory, revenues grow by 57% in nine months	AN
11-21	Laboratorio Farmaceutico Erfo 9m Ebitda EUR 1.7 mln	RE
29/09/25	Erfo Pharmaceutical Laboratory improves profits in the first half	AN
29/09/25	Erfo H1 EBITDA EUR 1.2 mln	RE
26/09/25	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/08/25	Laboratorio Erfo Reports Double-Digit Growth in Revenue and EBITDA for First Half	AN
28/08/25	Laboratorio Farmaceutico Erfo H1 ebitda eur 1.2 mln	RE
14/07/25	Laboratorio Farmaceutico Erfo Purchases 13,000 Own Ordinary Shares	AN
23/05/25	Laboratorio Erfo, revenues and EBITDA up significantly in the quarter	AN
23/05/25	Erfo Q1 EBITDA EUR 0.5 Mln	RE
21/05/25	Erfo presents Osteo-therapy, a nutraceutical supplement	AN
01/04/25	Laboratorio Farmaceutico Erfo FY EBITDA Adj EUR 1.4 MlN	RE